Lantheus updates merger proxy: analysts value Lantheus stock at USD 98.00-129.00
Lantheus Holdings updated its merger disclosures on October 2, 2026, ahead of an October 14, 2026 stockholder vote, revealing analyst valuations of USD 98.00-129.00 per share and Morgan Stanley's analyses valuing the stock at USD 63.85-118.60 per share. The proposed transaction offers USD 102.50 per share in cash plus potential contingent value rights up to USD 12.00, totaling up to USD 114.50 per share. The company also reported Q2 2026 revenue of USD 388.18 million, a 2.70% year-over-year increase, with a market capitalization of USD 6.5 billion as of October 5, 2026.
Lantheus Holdings stock faces an October 14 merger vote
Lantheus Holdings is preparing for an October 14, 2026, merger vote related to its proposed Curium transaction, amidst three complaints and 16 demand letters concerning merger disclosures. The company reported Q2 2026 revenue of $388.18 million and recently received CMS transitional pass-through status for PYLARIFY TruVu. Analyst consensus shows 14 firms with a "Hold" rating, and an average 12-month price target of $108.11, while the stock currently trades below its yearly high.
Lantheus Holdings discloses litigation, Morgan Stanley valuation ranges ahead of stockholder vote
Lantheus Holdings (LNTH) has provided supplemental disclosures, updated Morgan Stanley valuation analyses, and revealed related stockholder litigation ahead of its October 14 special meeting. Three lawsuits have been filed alleging proxy omissions and seeking to enjoin the merger, alongside sixteen demand letters requesting additional disclosures. The company furnished supplemental disclosures to mitigate litigation burden while denying any deficiencies.
Current ratio of Lantheus Holdings Inc – HAN:0L8
The article displays the current ratio for Lantheus Holdings Inc (HAN:0L8) on the Hannover Stock Exchange through TradingView. It provides financial data, but the specific current ratio value, change, and change percentage are not detailed in the provided text, only the placeholders for where they would appear.
Starting Oct. 1, Lantheus's prostate cancer scan qualifies for separate Medicare payment in hospital outpatient care.
Lantheus (NASDAQ: LNTH) has announced that its PYLARIFY TruVu prostate cancer imaging agent has received Transitional Pass-Through payment status from the Centers for Medicare & Medicaid Services (CMS), effective October 1, 2026. This designation enables separate reimbursement for the scan in hospital outpatient settings. Additionally, PYLARIFY TruVu has been assigned a permanent Healthcare Common Procedure Coding System (HCPCS) code, also effective October 1, 2026, to streamline billing and reimbursement for providers and support patient access.
Lantheus (LNTH) Stock May Be 14% Undervalued After FDA Approval
Lantheus Holdings (LNTH) stock is currently trading near US$99.74, with a recent FDA approval for BRAVNETSA and progress on the SPARROW prostate cancer imaging trial potentially reshaping future revenue expectations. A Discounted Cash Flow (DCF) model suggests the stock may be modestly undervalued based on its projected free cash flow, with a community narrative indicating it could be 7% undervalued. The article stresses the importance of further analysis beyond valuation, including leadership and track record.
Total equity of Lantheus Holdings Inc – HAN:0L8
This article provides financial information for Lantheus Holdings Inc (HAN:0L8) on the Hannover Stock Exchange, specifically focusing on its total equity. The page displays the company's financials and market data provided by various financial services.
CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection
The Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status to Lantheus Holdings Inc's PYLARIFY TruVu injection, effective October 1, 2026. This allows hospitals to receive separate reimbursement for the prostate cancer imaging agent in outpatient settings, potentially increasing its adoption. While the stock (LNTH) is considered modestly overvalued by GuruFocus, it boasts a strong GF Score and positive institutional interest.
Lantheus Holdings, Inc. (LNTH) Stock Price, News, Quote & History
This article provides a comprehensive overview of Lantheus Holdings, Inc. (LNTH), including its stock price, historical data, company profile, and financial performance. It details the company's diagnostic and therapeutic products for heart and cancer, its financial highlights, and analyst insights.
A patient receives an experimental prostate cancer scan; the later phase is expected to enroll about 400.
Lantheus (LNTH) has dosed the first patient in its SPARROW Phase 2/3 registrational trial for LNTH-2401, an investigational prostate cancer imaging agent. This gallium-68-labeled PET agent targets the gastrin-releasing peptide receptor (GRPR), aiming to expand understanding of prostate cancer biology. The Phase 3 portion of the study is projected to enroll approximately 400 participants to evaluate diagnostic performance, safety, and tolerability.
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
Lantheus Holdings (LNTH) recently received FDA approval for BRAVNETSA, a radiopharmaceutical for adult GEP NET patients, which has brought the company into focus. Despite recent short-term share price pressure, LNTH has shown strong long-term returns, with a 48.27% year-to-date return and 97.08% 1-year total shareholder return. The article suggests the stock is currently 7% undervalued based on its pipeline, deal structure with Curium, and long-term cash generation potential, projecting a fair value of $107 per share.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of Werewolf Therapeutics, Inc. (HOWL), Beazer Homes USA, Inc. (BZH), Lantheus Holdings Inc. (LNTH), and MarketAxess Holdings Inc. (MKTX). These investigations stem from proposed acquisitions of each company, with concerns focusing on whether the transactions offer fair value to shareholders and involved a fair process. Shareholders are encouraged to contact Brodsky & Smith for discussions regarding these investigations.
Lantheus Holdings (LNTH) Wins FDA Approval For BRAVNETSA, Is 7% Undervalued Enough?
Lantheus Holdings (LNTH) has received FDA approval for BRAVNETSA, a radiopharmaceutical for treating neuroendocrine tumors. Despite recent share price cooling, the company has shown strong 1-year and year-to-date gains, and is currently estimated to be 7% undervalued with a fair value of $107.22. Acquisitions are expected to enhance manufacturing and broaden its product portfolio in high-growth markets.
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake.
Lantheus Alpha Therapy, LLC, a subsidiary of Lantheus Holdings, Inc., reported multiple open-market sales of Perspective Therapeutics (CATX) common stock throughout September 2026, including a large sale of nearly 1.4 million shares on September 22, 2026. Despite these sales, Lantheus Alpha still directly holds 8,739,011 shares, representing a 7.7% stake in Perspective Therapeutics as of September 22, 2026. The reported percentage is based on 114,151,663 shares outstanding as of August 5, 2026, with Lantheus Holdings and Lantheus Medical Imaging sharing voting and dispositive power over these shares.
Lantheus wins FDA approval for Bravnetsa GEP-NET drug
Lantheus Holdings, Inc. received final FDA approval for Bravnetsa (PNT2003), a radiopharmaceutical therapeutically equivalent to Lutathera, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval comes as Lantheus prepares for a shareholder vote on its sale to Curium. While Bravnetsa's launch date and price are undisclosed, the approval secures Lantheus's position in the adult GEP-NET market ahead of the merger decision.
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally
Lantheus Holdings, Inc. (LNTH) has experienced a significant rally driven by strong quarterly earnings, FDA approval for PYLARIFY TruVu, and intensified takeover interest from PE-backed Curium Pharma. The company's shares gained 92.62% over the past 52 weeks, with a market capitalization of $6.55 billion. Polaris Capital Management's Global Equity Strategy highlighted LNTH's strong performance, although it noted that certain AI stocks might offer greater upside potential.
Lantheus wins final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate( for GEP-NETs
Lantheus Holdings has received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate) for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks the first radioligand therapy approved through the FDA's Abbreviated New Drug Application (ANDA) pathway, indicating its bioequivalence to the reference product LUTATHERA. BRAVNETSA offers a new targeted radiation treatment option for GEP-NETs, a rare cancer affecting the digestive system and pancreas, expanding Lantheus's radiopharmaceutical portfolio.
A radioactive cancer treatment becomes the first approved through the FDA’s abbreviated drug pathway
Lantheus (LNTH) has received final FDA approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a radiopharmaceutical treatment for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval marks the first radioligand therapy to be approved through the FDA's Abbreviated New Drug Application (ANDA) pathway, signifying it as bioequivalent and therapeutically equivalent to LUTATHERA®. The approval expands Lantheus's oncology portfolio and creates a new regulatory route for radiopharmaceuticals, though the company plans a thoughtful launch with no immediate commercial availability.
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors By Investing.com
Lantheus Holdings, Inc. announced that the FDA has approved BRAVNETSA (lutetium Lu 177 dotatate) for treating adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks the first radioligand therapy approved through the FDA’s Abbreviated New Drug Application pathway. The approval comes with warnings regarding potential side effects including radiation exposure, myelosuppression, and reproductive toxicity.
Lantheus Holdings stock faces a new Curium review window
Lantheus Holdings (LNTH) is undergoing a renewed 30-day antitrust review for its $8 billion acquisition of Curium, following a resubmission of the Hart-Scott-Rodino filing on September 21, 2026. The new waiting period is set to expire on October 21, 2026, though the merger is still anticipated to close in the first half of 2027. This regulatory milestone provides investors with clearer dates for monitoring the transaction's progress.
Dig: Lantheus Curium ACQ premature (H1 2027; mega)
Dealroom.co reported that a premature acquisition entry for Lantheus Holdings by Curium, valued at $8.0 billion, has been deleted. The acquisition is expected to close in H1 2027, with Curium acquiring Lantheus shares for $102.50 cash per share plus potential CVRs. Lantheus will remain an independent public company until the closing.
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each
Alpha Therapy, a 10% stakeholder in Lantheus Holdings (NASDAQ: LNTH) and Perspective Therapeutics, recently sold 42,129 shares of Lantheus at $3.11 each, retaining over 11.5 million shares. Additionally, the firm sold 113,914 shares of Perspective Therapeutics between $3.12 and $3.14 per share. These transactions provide updated insights into Alpha Therapy's holdings in both companies.
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each
Lantheus Holdings (NASDAQ: LNTH) sold 35,769 shares of Perspective Therapeutics at $3.12 per share on September 1, 2026. Despite this transaction, Lantheus Holdings remains a significant 10% owner, retaining 11,563,425 shares of Perspective Therapeutics. The sale was categorized under sale code S and pertains only to Perspective Therapeutics stock.
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus potential additional payments through Contingent Value Rights. The investigation aims to determine if Lantheus's board failed to secure the best possible price for shareholders, ensure a fair sales process, and disclose all material information. Shareholders are encouraged to contact the firm to discuss their rights.
Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH)
The article provides a Q2 recap for the healthcare equipment and supplies sector, focusing on Lantheus (NASDAQ:LNTH) and its peers. It highlights the sector's strong performance, driven by innovation, an aging population, and advancements in technology, despite challenges like pricing pressure and supply chain disruptions. The report details the financial results of Lantheus, Baxter, LeMaitre, Teleflex, and Inspire Medical Systems, assessing their revenue growth and EPS performance against analyst expectations.
Lantheus Holdings CAO Kimberly Brown Sells 463 Shares for Tax Withholding Purposes
Kimberly Brown, Chief Accounting Officer of Lantheus Holdings (NASDAQ:LNTH), sold 463 shares of common stock on August 17, 2026. This transaction, conducted at $100.91 per share, was for tax withholding purposes related to equity awards. Following the sale, Brown's direct ownership in the company stands at 13,263 common stock shares.
Lantheus Holdings, Inc. Stock 12‑Month Price Target Cut to $106.3, Implies 6% Upside
Lantheus Holdings, Inc.'s average 12-month price target has been adjusted to $106.3 by 8 analysts, a slight decrease from $107.16. This new target suggests a potential upside of approximately 6% from its August 18 closing price. The consensus rating for LNTH remains "Hold" among 11 analysts.
B.Riley downgrades Lantheus stock rating on Curium acquisition
B.Riley downgraded Lantheus Holdings (NASDAQ:LNTH) to Neutral from Buy and reduced its price target following Curium's agreement to acquire Lantheus. The acquisition is set at $102.50 per share plus potential contingent value rights, with the transaction expected to close in the first half of 2027. Despite the downgrade, InvestingPro data indicates Lantheus stock may still be undervalued.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for its radiodiagnostic agent, Tauklarify, for identifying tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used for PET imaging of the brain to identify tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. The approval was based on two blinded read studies demonstrating high accuracy and inter-reader agreement.
Lantheus Wins FDA Approval for Alzheimer's Tau PET Imaging Agent
Lantheus Holdings has received FDA approval for Tauklarify, a PET imaging agent designed to detect tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This approval comes as Lantheus prepares for an $8 billion acquisition by Curium and positions Tauklarify in a diagnostic market that has recently seen a rise in blood-based tests and disease-modifying therapies for Alzheimer's. The company plans to support therapeutic programs while determining the path for broader commercial availability.
FDA approves Lantheus tau PET imaging agent for Alzheimer’s disease
The FDA has approved Lantheus Holdings’ TauKlarify (florquinitau F 18 injection), a PET imaging agent for identifying tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease. While effective for Alzheimer's, its safety and effectiveness for other tauopathies have not been established. Lantheus plans to use TauKlarify for therapeutic development programs and is working towards broader commercial availability.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for Tauklarify, a radiodiagnostic agent designed to identify tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used in PET imaging of the brain to detect tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. This approval is based on two blinded read studies that demonstrated high accuracy and strong inter-reader agreement.
Tauklarify PET approval for Lantheus in AD NFT pathology
Lantheus Holdings announced FDA approval for Tauklarify (florquinitau F 18 injection), a radiodiagnostic agent for PET imaging of the brain to identify tau neurofibrillary tangle (NFT) pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. This approval is supported by two blinded read studies involving over 500 subjects. The company plans to continue supporting Alzheimer's therapeutic programs and assess broader commercial availability, noting the importance of tau PET imaging in understanding Alzheimer's.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection), an imaging drug for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology, with its approval backed by two studies demonstrating high accuracy. Lantheus plans to integrate Tauklarify into its Pharma Solutions business and evaluate broader commercial availability.
What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer’s Push?
Lantheus Holdings received FDA approval for TAUKLARIFY, a tau PET imaging agent for Alzheimer's disease diagnostics, expanding its molecular imaging portfolio beyond prostate cancer. This approval strengthens Lantheus's position in the Alzheimer's imaging market and supports its strategy of diversifying revenue and meeting the growing demand for early diagnosis of the disease. However, the company still faces execution risks and competition from other players in the PET imaging space.
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
This weekly roundup of the global biopharma sector highlights significant events including regulatory approvals, corporate restructuring, and clinical trial successes. Key approvals were granted to Lantheus, Akeso, Galderma, Rhythm Pharmaceuticals, Acarix, Ceribell, Labcorp, and Bavarian Nordic. Additionally, the article covers workforce reductions at Aura Biosciences, Schrödinger, and aTyr Pharma, major deals and acquisitions involving RTW Bio, Mereo BioPharma, Teledyne, Jazz Pharmaceuticals, and Oculis, and positive clinical trial readouts for Cullinan, NeOnc Technologies, Definium Therapeutics, and Silence Therapeutics.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial availability, with the approval backed by two studies showing high agreement in tau-PET image analysis.
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease
The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on two blinded read studies involving over 500 subjects, demonstrating high positive and negative percent agreement and inter-reader agreement.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Holdings Inc. has received FDA approval for its brain-imaging agent, Tauklarify (Florquinitau F 18 Injection), for assessing Alzheimer's disease through PET imaging. This approval allows for the detection of tau pathology in the brain, which is a key indicator of Alzheimer's. The company, focused on radiopharmaceuticals, aims to assist clinicians in diagnosing and monitoring diseases more effectively.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
The U.S. FDA has approved Lantheus Holdings' radioactive agent, Tauklarify, for use in brain scans to assess Alzheimer's disease by making abnormal tau protein deposits visible. This approval was based on two studies involving over 500 participants. While the tau-imaging market is currently dominated by Eli Lilly's Tauvid, analysts project Tauklarify sales to reach less than $50 million by 2030, noting that the clinical use of tau imaging is still limited as there is no approved Alzheimer's treatment specifically targeting tau.
FDA approves Lantheus brain scan to identify tau in Alzheimer’s
Lantheus has received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a PET imaging agent used to detect tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. The approval is based on two blinded read studies demonstrating high diagnostic performance. While it is not for non-Alzheimer’s tauopathies and has warnings about potential misdiagnosis and radiation risk, Lantheus plans to integrate it into its Pharma Solutions business for Alzheimer’s therapeutic programs.
Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus
Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. The shares are held through various investment partnerships managed by Farallon Capital Management, L.L.C., with managing and senior managing members exercising shared voting and dispositive power.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $108.11. The company recently exceeded earnings and revenue expectations, reporting $1.55 EPS and $388.18 million in revenue. Institutional investors hold a significant 99.06% of the stock, with several firms increasing their positions.
Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?
Lantheus Holdings (LNTH) is set to be acquired by Curium US LLC for up to US$8 billion, including US$102.50 cash per share and contingent value rights up to US$12.00 per share tied to product milestones. The stock currently trades at US$100.98, near the cash offer, and while analysts estimate a fair value of $104.08, the deal is expected to close in the first half of 2027, with the company remaining independent until then. This transaction introduces a blend of deal certainty and potential additional upside from the contingent value rights, but also carries risks related to deal completion and product performance.
Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?
Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) for US$102.50 in cash per share plus contingent value rights up to US$12.00 per share, with the deal expected to close in the first half of 2027. The article discusses whether the remaining upside is already priced in, noting that the stock currently trades close to the cash offer. It also highlights that analysts see the stock as modestly undervalued with a fair value of $104.08, but with potential risks if product performance doesn't meet expectations.
Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH
Pacer Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. by 97.0% in the first quarter, selling 247,589 shares and retaining 7,704 shares valued at $584,000. Despite this, other institutional investors have recently modified their holdings, and 99.06% of the stock is still owned by hedge funds and institutional investors. Lantheus reported strong quarterly earnings, beating analyst estimates, but analyst sentiment is mixed with several downgrades to "hold" ratings.
Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH
Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to "Hold." Institutional investors collectively own 99.06% of the company's stock.
Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position
Reinhart Partners LLC. has increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2%, making it their second-largest holding and comprising 4.1% of their portfolio. Despite this, analyst sentiment has softened, leading to several downgrades to "Hold" and a consensus price target of $108.11. Lantheus recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger
Lantheus Holdings (LNTH) stock saw a minimal price change despite solid Q2 earnings, with revenue meeting expectations and EPS remaining flat year-over-year. Investors are weighing the company's strong trailing P/E against questions about future growth pillars like Alzheimer’s diagnostics and operating leverage, especially after a slight decline in quarterly net income. The recent agreement for Curium to acquire Lantheus for up to US$8 billion further complicates the market's interpretation of its current performance and future prospects.
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential additional payments of up to $12.00 per share via Contingent Value Rights. KSF is assessing whether this offer and the process leading to it adequately value the company.
